Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxue Tongluo is a Traditional Chinese Medicine (TCM) botanical product developed by Jiangsu Kanion Pharmaceutical Co., Ltd. for the treatment of acute cerebral infarction and ischemic stroke. It is formulated as a powder for injection and is administered intravenously. The drug is specifically indicated for patients with "blood stasis blocking collaterals" syndrome, a TCM classification for certain types of stroke. Its therapeutic mechanism involves promoting blood circulation and dredging collaterals to improve neurological outcomes and reduce ischemic brain injury. The drug has been evaluated in Phase II clinical trials in China to assess its efficacy and safety in patients with acute cerebral infarction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huoxue Tongluo.